OR WAIT null SECS
© 2024 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
January 03, 2023
This compilation allows readers to adjust their thinking to appreciate the full impact certain select technologies will make on the industry by 2026.
Bio/pharma has evolved and adapted to a variety of challenges in 2022, but what might be on the cards for the industry in 2023?
Inhaled vaccines must resist degradation and penetrate the mucosal lining in the airways and lungs.
Cautiously setting aside pandemic practices, pharma workers appear ready for flux, change, evolution, and expanding molecular diversity.
Experts weigh in on trends in the biotechnology market, psychedelics, and India.
FDA sent a variety of warning letters to drug manufacturers at the end of 2022 highlighting myriad CGMP and quality control violations.
January 02, 2023
As the therapeutic landscape grows more complex, so too must the analytical techniques for cleaning validation to ensure the utmost cleanliness is achieved.
In light of increasingly stringent sustainability requirements, bio/pharma companies need to make sure they formulate effective ESG strategies.
CMOs are hoping to grow outsourcing to significantly higher levels in many different areas, with a focus on analytical testing, toxicity testing, and fill/finish operations.
Politics and drug shortages will continue to impact FDA and drug manufacturers in 2023.
Manufacturers automate production lines and increase the use of third-party providers.
Manufacturers must consider key components of manufacturing solid versus semi-solid drugs to create a successful end product.
From The Editor
Coverage of COVID-19 vaccines was surprisingly displaced by this year’s astounding oncology and iconoclastic gene therapy “cures.”
TreeFrog Therapeutics is leaping ahead in cell therapies through
resources such as new technologies and investor partnerships.
The latest report from Clarivate has been published, highlighting 15 potential blockbusters to watch out for in 2023, the majority of which are personalized medicines.
Does the new regulatory framework have the potential to incentivise R&D investment in rare diseases?
Ask the Expert
A CCS provides significant benefits to the industry and helps with holistically understanding contamination controls, says Siegfried Schmitt, vice president, Technical at Parexel.
The ROSS Model HSM-405SC-25 Inline High Shear Mixer with SLIM Technology is a flexible mixing solution.
Particle Measuring Systems’ MiniCapt Pro Remote Microbial Air Sampler is designed for effective remote microbial monitoring for cleanroom professionals.
Celegance’s Dossplorer can import product registration dossiers and ready regulatory submissions for electronic common technical documents compliance.
Bio-Rad Laboratories’ Pioneer Antibody Discovery Platform is an antibody discovery service specifically designed to develop best-in-class biologic candidates.
From the CEO
Cell and gene therapies is unequivocally viewed as the biggest opportunity in the bio/pharma space.